文献速递血管炎

既往糖皮质激素治疗对巨细胞动脉炎中[18F]FDG PET-CT诊断准确性的影响

Impact of previous glucocorticoid therapy on diagnostic accuracy of [18F] FDG PET-CT in giant cell arteritis.
PubMed 文献 · Semin Arthritis Rheum · 2023-02-18

回顾性连续队列研究纳入85例确诊巨细胞动脉炎且PET-CT前接受高剂量糖皮质激素的患者,评估既往激素治疗对PET-CT诊断准确性的影响。结果显示甲泼尼龙剂量越高PET-CT阳性率越低,新发患者口服激素疗程越长阳性率越低,复发/难治或既往有风湿性多肌痛病史者长期中低剂量激素下阳性率仍达54%。结论认为治疗10天后的晚期PET-CT在相当比例病例中仍可提供信息。

要点

  • 甲泼尼龙125mg组PET-CT阳性率80%,250或500mg组33%,1g组0%。
  • 新发患者口服激素<2周阳性率54.5%,2-4周38.5%,4-6周25%。
  • 复发/难治或既往风湿性多肌痛者长期中低剂量激素下阳性率54%。

核心结论

  • 治疗10天后的晚期18F-FDG PET-CT在相当比例病例中仍可提供信息。

研究设计与样本

  • 回顾性研究,连续队列纳入85例确诊巨细胞动脉炎且PET-CT前接受高剂量糖皮质激素的患者。

主要发现

  • 39例既往接受甲泼尼龙冲击治疗,其中37%为PET-CT阳性(摄取分级3级或2级)。
  • 甲泼尼龙125mg组PET-CT阳性率80%,250或500mg组33%,1g组0%。
  • 若将1级摄取(环形摄取且平滑线状或长节段模式,可能提示「看似不活动」的血管炎)也计为阳性,阳性率升至62%(不同甲泼尼龙剂量分别为100%、50-60%和33%)。
  • 新发巨细胞动脉炎接受高剂量口服糖皮质激素者,治疗<2周PET-CT阳性率54.5%,2-4周38.5%,4-6周25%;若纳入具有上述特征的1级摄取病例,分别升至91%、77%和50%。
  • 复发/难治性巨细胞动脉炎或既往有风湿性多肌痛病史后发生巨细胞动脉炎者,尽管长期接受中低剂量糖皮质激素,PET-CT阳性率达54%(纳入1级摄取病例为68%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of prior glucocorticoid (GC) treatment on the diagnostic accuracy of 18F-FDG PET-CT in giant cell arteritis (GCA). METHODS: Retrospective study of a consecutive cohort of 85 patients with proven GCA who received high-dose GC before PET-CT. RESULTS: Thirty-nine patients previously treated with methylprednisolone (MP) boluses, of whom 37% were PET-CT (uptakes grade 3 or 2) positive. The positivity rate was 80% with MP doses of 125 mg, 33% with 250 or 500 mg, and 0% with doses of 1 g. If we also classify as positive those cases with a grade 1 uptake (with a circumferencial uptake and smooth linear or long segmental pattern, possibly indicative of "apparently inactive" vasculitis), the positivity rate increases to 62% (100%, 50-60%, and 33% for the different MP doses, respectively). In patients with new-onset GCA treated with high-dose oral GC, PET-CT positivity was 54.5% in patients treated for less than two weeks, 38.5% in those treated for 2 to 4 weeks, and 25% in those treated for 4 to 6 weeks (increasing to 91%, 77%, and 50%, respectively, if we include cases with grade 1 uptake and these characteristics). In patients with relapsing/refractory GCA, or who developed GCA having a prior history of PMR, PET-CT positivity reached 54% despite long-term treatment with low-to-moderate doses of GC (68% including cases with a grade 1 uptake). CONCLUSION: A late 18F-FDG PET-CT (beyond the first 10 days of treatment) can also be informative in a considerable percentage of cases.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Narváez J, Estrada P, Vidal-Montal P, et al. Impact of previous glucocorticoid therapy on diagnostic accuracy of [18F] FDG PET-CT in giant cell arteritis. Semin Arthritis Rheum. 2023. PMID: 36841055. doi:10.1016/j.semarthrit.2023.152183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。